In this regard, information on tumor histopathology, routinely collected at the time of diagnoses, such as histological grade, the status of estrogen, progesterone, or HER-2, as well as identification of cell proliferation markers, can be incorporated into the criteria already recommended for investigation of the risk of hereditary breast and ovarian cancer, aiming to strengthen and expand the adoption of a practical strategy for genetic evaluation in patients with breast cancer. This evidence concerns the gene ERBB2 and ovarian cancer.